ENCell (KOSDAQ:A456070) - Stock Price, News & Analysis

A456070 Stock Overview

Develops cell/gene-based biopharmaceutical products in South Korea. More details

A456070 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the KR market

ENCell Co., Ltd. Competitors

Macrogen

KOSDAQ:A038290

₩161.2b

HLB bioStepLtd

KOSDAQ:A278650

₩178.1b

NanoEntek

KOSDAQ:A039860

₩108.5b

Curiox Biosystems

KOSDAQ:A445680

₩313.7b

Price History & Performance

Summary of all time highs, changes and price drops for ENCell
Historical stock prices
Current Share Price	₩16,930.00
52 Week High	₩45,800.00
52 Week Low	₩13,010.00
Beta	0
11 Month Change	-16.40%
3 Month Change	-55.68%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-1.57%

Recent updates

Shareholder Returns

	A456070	KR Life Sciences	KR Market
7D	30.0%	0.5%	0.9%
1Y	n/a	33.0%	-3.4%

Return vs Industry: Insufficient data to determine how A456070 performed against the KR Life Sciences industry.

Return vs Market: Insufficient data to determine how A456070 performed against the KR Market.

Price Volatility

Is A456070's price volatile compared to industry and market?
A456070 volatility
A456070 Average Weekly Movement	18.0%
Life Sciences Industry Average Movement	8.7%
Market Average Movement	5.7%
10% most volatile stocks in KR Market	11.6%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A456070's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A456070's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	n/a	encellinc.com

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.

ENCell Co., Ltd. Fundamentals Summary

How do ENCell's earnings and revenue compare to its market cap?
A456070 fundamental statistics
Market cap	₩154.38b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A456070 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A456070 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A456070 perform over the long term?

See historical performance and comparison

ENCell KOSDAQ:A456070 Stock Report